Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...

U.S. FDA Approves Terumo BCT’s Sodium Citrate 4% w/v Anticoagulant Solution Amid Shortage Lakewood, Colorado, USA, July 18, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) recently approved Terumo BCT’s Sodium Citrate 4% w/v Anticoagulant Solution USP, indicated for...